The Effect of Creatine Monohydrate on Persistent Post-concussive Symptoms

NCT ID: NCT05562232

Last Updated: 2024-07-12

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 45 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-08-01
• Study Completion Date: 2024-12-31

Brief Summary

The purpose of this study, is to investigate whether creatine monohydrate as a supplement reduces the number and severity of symptoms in patients with persistent post-concussive symptoms through self-reported post-concussion symptoms questionnaires.

Detailed Description

Mild traumatic brain injury (mTBI), which throughout the literature is used interchangeably with concussion, is a problem of public concern. It is estimated that between 0.6 % and 1.2 % of the general population will suffer an mTBI each year which equals to 48-96 millions of people on a world scale. Out of these, an estimated 10-30 % of the patients, will suffer from persistent PPCS. These symptoms typically includes headache, poor concentration, memory problems, fatigue, sleep difficulties, dizziness, irritability, feeling nervous or anxious. PPCS has proven to be not only a health problem, but also a socioeconomical problem. Data has showed that salary in Denmark five years after a concussion decreased 4.2 %, with an increased risk of losing ones job. At the moment no single treatment option is available with guaranteed success, and therefore nutritional supplements are a possibility.

The nutritional supplement CrM is one of the most popular ergogenic aids on the market among professional and amateur athletes. It is mostly used in the development of muscle mass, as creatine is primarily located skeletal muscle. Roughly five percent of the body's creatine is distributed in the brain and testicles. As mTBI's also see a change in the metabolism of the brain, creatine supplementation might be beneficial for patients with PPCS. This is further supported by a newly conducted study, that creatine supplementation may reduce the severity of mild concussion in animal models.

Furthermore, as the enzyme Creatine Kinease (CK), which is involved in ATP energy system, also has a brain specific isoform (BB-CK), creatine may be a relevant part of the energy system of the central nervous system (CNS). In addition evidence points towards creatine supplementation can increase cellular energy availability. It has been reported to increase brain phosphocreatine content by as much as 15 %, which in turn improves the metabolic processes of the brain.

CrM has been described to be a potent anti-inflammatory molecule. It has been shown to reduce the cytotoxic effects in oxidatively-injured cells without affecting antioxidant enzyme activities, and has been shown to inhibit reactive oxygen species-induced formation of mitochondrial permeability transition pores in the liver mitochondria of mice. At the same time, concussion seems to increase inflammation in the brain, and this inflammation has been hypothesized to correlate with the symptomatology and duration. And even though research in the area of recovery is still scarce, neuroinflammation seems to play a vital role in the pathophysiology of concussions. This warrants hopes of a decrease in post-concussive symptoms.

Other studies have indicated an improvement of cognitive functions, including fatigue, working memory and mood state. All symptoms related to PPCS. Additionally evidence points towards creatine supplementation can help with chronic fatigue, depression and anxiety. All this points towards CrM being helpful in the treatment of PPCS.

Currently there is not viable treatment option for these patients, but if the intervention shows positive results, patients suffering from PPCS would be able to improve on their symptoms, relatively easy and cheap. They would have a go-to supplement, that would make it possible for them to get a normal day, without any of the symptoms connected to PPCS.

The pilot study will be performed as a randomized controlled trial in accordance with the Spirit Guidelines. The study is expected to include a convenience sample of 45 patients. The patients will randomly be allocated to either a control group, placebo group or intervention group, with 15 patients in each. The study will be double blinded, i.e., the participants and personel not knowing which group the patients will be allocated to. Furthermore, the process of randomization will consist of a nutritionist not otherwise associated with the study, randomly allocating each participant in a group, until sample size is reached. The person in charge of this, will also be distributing either the placebo or the CrM to the participants in each of these groups.

CG will not receive any treatment other than usual treatment. PLA and INT will both receive a powder, that has to be ingested. PLA will receive a powder similar in looks to CrM, but with no apparent nutritional value, while INT will receive CrM.

As both PLA and INT are the interventions, they will follow the same protocol for ingestion: 5 grams pr day in seven weeks. All 5 grams will be ingested at once. This protocol has been chosen instead of the more common 0.3 g/day for the first week, ingested over five times during the day. In other studies on CrM and the brain, this have been the chosen strategy also. But studies on CrM in the muscles show, that both protocols illicit the same response with 28 days, and the loading phase is not required. Furthermore, some studies have used this protocol with creatine supplementation, and found increased cognitive function. Our reason for choosing 5 g/day in seven weeks, is to increase the chances of compliance, and decrease the risks of discomfort with to high an intake of CrM. An intake five times a day for the first week, is demanding, and will most likely get some participants to quit the study.

At the mid phase of the study, all baseline measurements will be done again. The length of the intervention is seven weeks. After the seven weeks, all baseline measurements will be done again. And a week after last ingestion, the measurements will be done one last time. At the week eight appointment, every participant will have to answer whether they thought they were getting placebo or CrM. This is done in order to figure out how big an effect placebo have on the results.

The control group will receive standard care. However, to our knowledge there is no common accepted description of a standard care in the literature., In general, these participants will be advised to keep themselves as asymptomatic as possible throughout the entire seven weeks, and besides that live as normal a life as they can.

The study population will be patients with persistent post-concussive symptoms between six and twelve months at start of participation. Participants will be recruited through social media and fourteen neurological outpatient clinics located in Denmark. At the start of the study, participants will have to be between 25 and 35 years of age. This will make the population a homogenous age group, and we will avoid physical and cognitive challenges related to early childhood and adolescents, as well as avoiding the degeneration in physical capacities that begin at approximately the age of 35, as well as the cognitive decline around the same time.

The anthropometrics of the participants will consist of age (years), gender (male/female), height (cm), bodymass (kg), period with PPCS (months), concussion history (yes/no), if yes, then how many (number), and training status (hours/week).

Conditions

Mild Traumatic Brain Injury; Concussion, Brain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Intervention group

Creatine monohydrate administered once a day for seven weeks - with 5 g/day for the entire period.

Group Type: EXPERIMENTAL

Creatine Monohydrate

Intervention Type: DIETARY_SUPPLEMENT

Follows

Control group

The control group will receive standard care. However, to our knowledge there is no common accepted description of a standard care in the literature. In general, these participants will be advised to keep themselves as asymptomatic as possible throughout the entire seven weeks, and besides that live as normal a life as they can.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Placebo

Powdered Sugar administered once a day for seven weeks - with 5g/day for the entire period.

Group Type: PLACEBO_COMPARATOR

Creatine Monohydrate

Intervention Type: DIETARY_SUPPLEMENT

Follows

Interventions

Creatine Monohydrate

Follows

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Have had PPCS for a minimum of six months and a maximum of 18 months at the start of the study.
• Being between 20 and 45 years of age

Exclusion Criteria

• Elite athletes, as well as people who in general is physical active, at an intensity of moderat to high, for more than ten hours a week on average.
• Participation in other interventions/treatment that could affect this study
• Have had PPCS in:
• =<6 months
• =>18 months
• Pregnant

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University of Southern Denmark

OTHER

Sponsor Role: collaborator

Psychiatric Research Unit, Region Zealand, Denmark

OTHER

Sponsor Role: lead

Responsible Party

Michael Haurum Marcussen

Dr.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Michael Marcussen, Dr.

Role: PRINCIPAL_INVESTIGATOR

University of Southern Denmark (SDU), Denmark

Locations

University of Southern Denmark

Odense, , Denmark

Site Status: RECRUITING

Countries

Denmark

Central Contacts

Ronni Lykke Bødker, MSc

Role: CONTACT

ronni@commotio.dk

+45 61710188

Michael Marcussen, Dr.

Role: CONTACT

mhmarcussen@health.sdu.dk

+4526369503

Facility Contacts

Michael H Marcussen, Ph.D.

Role: primary

mhmarcussen@health.sdu.dk

References

McCrory P, Meeuwisse W, Dvorak J, Aubry M, Bailes J, Broglio S, Cantu RC, Cassidy D, Echemendia RJ, Castellani RJ, Davis GA, Ellenbogen R, Emery C, Engebretsen L, Feddermann-Demont N, Giza CC, Guskiewicz KM, Herring S, Iverson GL, Johnston KM, Kissick J, Kutcher J, Leddy JJ, Maddocks D, Makdissi M, Manley GT, McCrea M, Meehan WP, Nagahiro S, Patricios J, Putukian M, Schneider KJ, Sills A, Tator CH, Turner M, Vos PE. Consensus statement on concussion in sport-the 5th international conference on concussion in sport held in Berlin, October 2016. Br J Sports Med. 2017 Jun;51(11):838-847. doi: 10.1136/bjsports-2017-097699. Epub 2017 Apr 26. No abstract available.

Reference Type: BACKGROUND

PMID: 28446457 (View on PubMed)

Cassidy JD, Carroll LJ, Peloso PM, Borg J, von Holst H, Holm L, Kraus J, Coronado VG; WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. Incidence, risk factors and prevention of mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. 2004 Feb;(43 Suppl):28-60. doi: 10.1080/16501960410023732.

Reference Type: BACKGROUND

PMID: 15083870 (View on PubMed)

Langer L, Levy C, Bayley M. Increasing Incidence of Concussion: True Epidemic or Better Recognition? J Head Trauma Rehabil. 2020 Jan/Feb;35(1):E60-E66. doi: 10.1097/HTR.0000000000000503.

Reference Type: BACKGROUND

PMID: 31246881 (View on PubMed)

Makdissi M, Schneider KJ, Feddermann-Demont N, Guskiewicz KM, Hinds S, Leddy JJ, McCrea M, Turner M, Johnston KM. Approach to investigation and treatment of persistent symptoms following sport-related concussion: a systematic review. Br J Sports Med. 2017 Jun;51(12):958-968. doi: 10.1136/bjsports-2016-097470. Epub 2017 May 8.

Reference Type: BACKGROUND

PMID: 28483928 (View on PubMed)

Levin HS, Diaz-Arrastia RR. Diagnosis, prognosis, and clinical management of mild traumatic brain injury. Lancet Neurol. 2015 May;14(5):506-17. doi: 10.1016/S1474-4422(15)00002-2. Epub 2015 Mar 20.

Reference Type: BACKGROUND

PMID: 25801547 (View on PubMed)

Fallesen P, Campos B. Effect of concussion on salary and employment: a population-based event time study using a quasi-experimental design. BMJ Open. 2020 Oct 21;10(10):e038161. doi: 10.1136/bmjopen-2020-038161.

Reference Type: BACKGROUND

PMID: 33087373 (View on PubMed)

Kreider RB, Kalman DS, Antonio J, Ziegenfuss TN, Wildman R, Collins R, Candow DG, Kleiner SM, Almada AL, Lopez HL. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. J Int Soc Sports Nutr. 2017 Jun 13;14:18. doi: 10.1186/s12970-017-0173-z. eCollection 2017.

Reference Type: BACKGROUND

PMID: 28615996 (View on PubMed)

Romeu-Mejia R, Giza CC, Goldman JT. Concussion Pathophysiology and Injury Biomechanics. Curr Rev Musculoskelet Med. 2019 Jun;12(2):105-116. doi: 10.1007/s12178-019-09536-8.

Reference Type: BACKGROUND

PMID: 30820754 (View on PubMed)

Kreider RB, Stout JR. Creatine in Health and Disease. Nutrients. 2021 Jan 29;13(2):447. doi: 10.3390/nu13020447.

Reference Type: BACKGROUND

PMID: 33572884 (View on PubMed)

Smith RN, Agharkar AS, Gonzales EB. A review of creatine supplementation in age-related diseases: more than a supplement for athletes. F1000Res. 2014 Sep 15;3:222. doi: 10.12688/f1000research.5218.1. eCollection 2014.

Reference Type: BACKGROUND

PMID: 25664170 (View on PubMed)

Lowe MT, Faull RL, Christie DL, Waldvogel HJ. Distribution of the creatine transporter throughout the human brain reveals a spectrum of creatine transporter immunoreactivity. J Comp Neurol. 2015 Apr 1;523(5):699-725. doi: 10.1002/cne.23667. Epub 2014 Sep 12.

Reference Type: BACKGROUND

PMID: 25159005 (View on PubMed)

Whyte MP, Chines A, Silva DP Jr, Landt Y, Ladenson JH. Creatine kinase brain isoenzyme (BB-CK) presence in serum distinguishes osteopetroses among the sclerosing bone disorders. J Bone Miner Res. 1996 Oct;11(10):1438-43. doi: 10.1002/jbmr.5650111010.

Reference Type: BACKGROUND

PMID: 8889843 (View on PubMed)

Roschel H, Gualano B, Ostojic SM, Rawson ES. Creatine Supplementation and Brain Health. Nutrients. 2021 Feb 10;13(2):586. doi: 10.3390/nu13020586.

Reference Type: BACKGROUND

PMID: 33578876 (View on PubMed)

Hanna-El-Daher L, Braissant O. Creatine synthesis and exchanges between brain cells: What can be learned from human creatine deficiencies and various experimental models? Amino Acids. 2016 Aug;48(8):1877-95. doi: 10.1007/s00726-016-2189-0. Epub 2016 Feb 10.

Reference Type: BACKGROUND

PMID: 26861125 (View on PubMed)

Sestili P, Martinelli C, Bravi G, Piccoli G, Curci R, Battistelli M, Falcieri E, Agostini D, Gioacchini AM, Stocchi V. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006 Mar 1;40(5):837-49. doi: 10.1016/j.freeradbiomed.2005.10.035. Epub 2005 Nov 2.

Reference Type: BACKGROUND

PMID: 16520236 (View on PubMed)

O'Gorman E, Beutner G, Dolder M, Koretsky AP, Brdiczka D, Wallimann T. The role of creatine kinase in inhibition of mitochondrial permeability transition. FEBS Lett. 1997 Sep 8;414(2):253-7. doi: 10.1016/s0014-5793(97)01045-4.

Reference Type: BACKGROUND

PMID: 9315696 (View on PubMed)

Watanabe A, Kato N, Kato T. Effects of creatine on mental fatigue and cerebral hemoglobin oxygenation. Neurosci Res. 2002 Apr;42(4):279-85. doi: 10.1016/s0168-0102(02)00007-x.

Reference Type: BACKGROUND

PMID: 11985880 (View on PubMed)

Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proc Biol Sci. 2003 Oct 22;270(1529):2147-50. doi: 10.1098/rspb.2003.2492.

Reference Type: BACKGROUND

PMID: 14561278 (View on PubMed)

Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D. Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials. Exp Gerontol. 2018 Jul 15;108:166-173. doi: 10.1016/j.exger.2018.04.013. Epub 2018 Apr 25.

Reference Type: BACKGROUND

PMID: 29704637 (View on PubMed)

Bakian AV, Huber RS, Scholl L, Renshaw PF, Kondo D. Dietary creatine intake and depression risk among U.S. adults. Transl Psychiatry. 2020 Feb 3;10(1):52. doi: 10.1038/s41398-020-0741-x.

Reference Type: BACKGROUND

PMID: 32066709 (View on PubMed)

Bender A, Klopstock T. Creatine for neuroprotection in neurodegenerative disease: end of story? Amino Acids. 2016 Aug;48(8):1929-40. doi: 10.1007/s00726-015-2165-0. Epub 2016 Jan 9.

Reference Type: BACKGROUND

PMID: 26748651 (View on PubMed)

Sowell ER, Thompson PM, Holmes CJ, Jernigan TL, Toga AW. In vivo evidence for post-adolescent brain maturation in frontal and striatal regions. Nat Neurosci. 1999 Oct;2(10):859-61. doi: 10.1038/13154. No abstract available.

Reference Type: BACKGROUND

PMID: 10491602 (View on PubMed)

Johnson SB, Blum RW, Giedd JN. Adolescent maturity and the brain: the promise and pitfalls of neuroscience research in adolescent health policy. J Adolesc Health. 2009 Sep;45(3):216-21. doi: 10.1016/j.jadohealth.2009.05.016.

Reference Type: BACKGROUND

PMID: 19699416 (View on PubMed)

Westerstahl M, Jansson E, Barnekow-Bergkvist M, Aasa U. Longitudinal changes in physical capacity from adolescence to middle age in men and women. Sci Rep. 2018 Oct 3;8(1):14767. doi: 10.1038/s41598-018-33141-3.

Reference Type: BACKGROUND

PMID: 30283061 (View on PubMed)

Peters R. Ageing and the brain. Postgrad Med J. 2006 Feb;82(964):84-8. doi: 10.1136/pgmj.2005.036665.

Reference Type: BACKGROUND

PMID: 16461469 (View on PubMed)

King NS, Crawford S, Wenden FJ, Moss NE, Wade DT. The Rivermead Post Concussion Symptoms Questionnaire: a measure of symptoms commonly experienced after head injury and its reliability. J Neurol. 1995 Sep;242(9):587-92. doi: 10.1007/BF00868811.

Reference Type: BACKGROUND

PMID: 8551320 (View on PubMed)

Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol. 1999 Sep;277(3):R698-704. doi: 10.1152/ajpregu.1999.277.3.R698.

Reference Type: BACKGROUND

PMID: 10484486 (View on PubMed)

Lyoo IK, Kong SW, Sung SM, Hirashima F, Parow A, Hennen J, Cohen BM, Renshaw PF. Multinuclear magnetic resonance spectroscopy of high-energy phosphate metabolites in human brain following oral supplementation of creatine-monohydrate. Psychiatry Res. 2003 Jun 30;123(2):87-100. doi: 10.1016/s0925-4927(03)00046-5.

Reference Type: BACKGROUND

PMID: 12850248 (View on PubMed)

Antonio J, Candow DG, Forbes SC, Gualano B, Jagim AR, Kreider RB, Rawson ES, Smith-Ryan AE, VanDusseldorp TA, Willoughby DS, Ziegenfuss TN. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? J Int Soc Sports Nutr. 2021 Feb 8;18(1):13. doi: 10.1186/s12970-021-00412-w.

Reference Type: BACKGROUND

PMID: 33557850 (View on PubMed)

Ling J, Kritikos M, Tiplady B. Cognitive effects of creatine ethyl ester supplementation. Behav Pharmacol. 2009 Dec;20(8):673-9. doi: 10.1097/FBP.0b013e3283323c2a.

Reference Type: BACKGROUND

PMID: 19773644 (View on PubMed)

Harmon KG, Clugston JR, Dec K, Hainline B, Herring S, Kane SF, Kontos AP, Leddy JJ, McCrea M, Poddar SK, Putukian M, Wilson JC, Roberts WO. American Medical Society for Sports Medicine position statement on concussion in sport. Br J Sports Med. 2019 Feb;53(4):213-225. doi: 10.1136/bjsports-2018-100338.

Reference Type: BACKGROUND

PMID: 30705232 (View on PubMed)

Belanger M, Allaman I, Magistretti PJ. Differential effects of pro- and anti-inflammatory cytokines alone or in combinations on the metabolic profile of astrocytes. J Neurochem. 2011 Feb;116(4):564-76. doi: 10.1111/j.1471-4159.2010.07135.x. Epub 2011 Jan 19.

Reference Type: BACKGROUND

PMID: 21143598 (View on PubMed)

Balalla S, Krageloh C, Medvedev O, Siegert R. Is the Rivermead Post-Concussion Symptoms Questionnaire a Reliable and Valid Measure to Assess Long-Term Symptoms in Traumatic Brain Injury and Orthopedic Injury Patients? A Novel Investigation Using Rasch Analysis. Neurotrauma Rep. 2020 Aug 11;1(1):63-72. doi: 10.1089/neur.2020.0017. eCollection 2020.

Reference Type: BACKGROUND

PMID: 34223531 (View on PubMed)

Eyres S, Carey A, Gilworth G, Neumann V, Tennant A. Construct validity and reliability of the Rivermead Post-Concussion Symptoms Questionnaire. Clin Rehabil. 2005 Dec;19(8):878-87. doi: 10.1191/0269215505cr905oa.

Reference Type: BACKGROUND

PMID: 16323387 (View on PubMed)

Bodker RL, Marcussen M. Pilot study protocol of a randomized controlled trial for the potential effects of creatine monohydrate on persistent post-concussive symptoms. Front Neurol. 2023 Jul 5;14:1209548. doi: 10.3389/fneur.2023.1209548. eCollection 2023.

Reference Type: DERIVED

PMID: 37475743 (View on PubMed)

Other Identifiers

PRURegionZealand4

Identifier Type: -

Identifier Source: org_study_id